Entasis Therapeutics Holdings Inc.

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Otsuka Pays $10m Up Front For Ion

The US Food and Drug Administration approvals of Day One Biopharmaceuticals, LLC ’s Ojemda (tovorafenib) and ImmunityBio Inc. ’s Anktiva (nogapendekin alfa inbakicept-pmln) last week provided a boos

The sustainable supply of drugs for antimicrobial resistance (AMR) is needed on a global scale. However, this will require both pull incentive models for reimbursement and high technology for producin